Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Summit Therapeutics Inc.
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
August 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024
July 29, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
July 25, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
June 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
June 01, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
May 31, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
May 30, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
May 01, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
April 24, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
April 11, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
April 10, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
March 14, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
March 05, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
February 20, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
February 14, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
November 02, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
October 31, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
October 26, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
October 19, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
October 16, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
August 02, 2023
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.